Site search
Bibliography
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation
BACKGROUND: Rimonabant is a selective type 1 cannabinoid (CB1) receptor antagonist. It may assist with smoking cessation by restoring the balance of the endocannabinoid system, which can be disrupted by prolonged use of nicotine....
The Endocannabinoid Anandamide Inhibits the Function of {alpha}4{beta}2 Nicotinic Acetylcholine Receptors
NIDA Intramural Research Program.
The effects of the endocannabinoid anandamide (arachidonylethanolamide, AEA) on the function of alpha4beta2 nicotinic acetylcholine receptors (nAChR) stably expressed in SH-EP1 cells were...
Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users
Clinical Pharmacology and Therapeutics Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, 21224, USA, mhuestis@intra.nida.nih.gov.
RATIONALE: A single...
The endocannabinoid system: a new target for the regulation of energy balance and metabolism
Québec Heart Institute, Québec QC, Canada. jean-pierre.despres@crhl.ulaval.ca
Recent studies have provided evidence that the endocannabinoid (EC) system has very significant effects on energy balance and metabolism through the...
Cardiovascular disease under the influence of excess visceral fat
Québec Heart Institute, Québec, QC, Canada. jean-pierre.despres@crhl.ulaval.ca
Diabetes and cardiovascular disease have emerged as major threats to human health, and the risk of developing these chronic conditions is increased...
Displaying results 6 to 10 out of 15
This section of the site is dedicated to published Rimonabant related scientific studies that discuss its use and effects.